Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia

Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered role...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Maharaj, Kamira, Powers, John J., Achille, Alex, Deng, Susan, Fonseca, Renee, Pabon-Saldana, Mibel, Quayle, Steven N., Jones, Simon S., Villagra, Alejandro, Sotomayor, Eduardo M., Sahakian, Eva, Pinilla-Ibarz, Javier
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234358/
https://ncbi.nlm.nih.gov/pubmed/30425065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018020065
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados